Merger Monthly: After Novel Omnicom/Interpublic, HPE/Juniper Remedies, is Everything Settleable?; Outlook for Key Transactions Including Getty/Shutterstock, Mars/Kellanova, and UnitedHealth/Amedisys

Published on Jul 10, 2025

In the months after Inauguration Day, the Trump administration’s merger policy appeared to be slowly but surely rounding into form: To wit, meaningful continuity from the Biden administration (retaining the 2023 Merger Guidelines and updated HSR Form), coupled with substantive pull back on the margins (DOJ leadership’s decision not to challenge Capital One’s acquisition of […]

Novo Nordisk: Company Did Not Report or Investigate Deaths Potentially Caused by Ozempic

Novo Nordisk (NVO) did not report multiple deaths that may have been caused by its blockbuster weight loss drug Ozempic to the FDA, according to an agency inspection report obtained by The Capitol...

Jul 15, 2025 Read Now >

Antitrust Agenda: DOJ Indicts Oak View Group CEO for Arena Bid Rigging; Low Efficacy of Post-Merger Divestitures Indicates Need for Stronger Enforcement, New Paper Concludes; Manufacturers Neglect of Repair Manuals and Materials Could Run Afoul of Right-to-Repair Laws

Live entertainment executive indicted on criminal bid-rigging charges. The Justice Department last Wednesday indicted Timothy Leiweke, the CEO of the live entertainment company Oak View Group (OVG),...

Jul 14, 2025 Read Now >

Prestige Consumer Healthcare: Subsidiary Kept Mold-Contaminated Enemas on Market and Declined to Investigate Source of Outbreak, According to FDA Inspection

Between 2023 and 2025, Fleet, a subsidiary of Prestige Consumer Healthcare (PBH) that manufactures enemas and suppositories, received several complaints that its adult and pediatric enemas were being...

Jul 11, 2025 Read Now >

Merger Monthly: After Novel Omnicom/Interpublic, HPE/Juniper Remedies, is Everything Settleable?; Outlook for Key Transactions Including Getty/Shutterstock, Mars/Kellanova, and UnitedHealth/Amedisys

RELATED ARTICLES | Editor’s picks

Novo Nordisk: Company Did Not Report or Investigate Deaths Potentially Caused by Ozempic

Antitrust Agenda: DOJ Indicts Oak View Group CEO for Arena Bid Rigging; Low Efficacy of Post-Merger Divestitures Indicates Need for Stronger Enforcement, New Paper Concludes; Manufacturers Neglect of Repair Manuals and Materials Could Run Afoul of Right-to-Repair Laws

Prestige Consumer Healthcare: Subsidiary Kept Mold-Contaminated Enemas on Market and Declined to Investigate Source of Outbreak, According to FDA Inspection

FILTER BY

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.